文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

年龄相关:院前氨甲环酸治疗创伤性脑损伤试验中内皮生物标志物的二次分析

Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial.
PubMed 文献 · J Trauma Acute Care Surg · 2025-03-20
一句话结论创伤性脑损伤患者中,老年组入院时内皮生物标志物(血栓调节蛋白、VCAM-1、血管紧张素2)高于年轻组,且2g氨甲环酸对老年组内皮标志物的影响与年轻组不同,但无标志物能独立预测28天死亡率。

该研究为院前氨甲环酸治疗创伤性脑损伤数据库(2015-2017)的回顾性二次分析,共纳入436例有入院内皮生物标志物检测的创伤患者,按年龄四分位数分组,比较最大四分位(老年组,平均66岁,n=108)与其余三个四分位(年轻组,平均30岁,n=328)。两组钝性创伤比例、头部简明损伤定级和损伤严重度评分无显著差异。老年组入院时血栓调节蛋白(中位693.3 vs 592.9 pg/mL,p=0.0008)、VCAM-1(中位70,852 vs 59,738 pg/mL,p=0.0015)和血管紧张素2(中位165.3 vs 134.2 pg/mL,p=0.005)显著高于年轻组。在2g氨甲环酸亚组中,老年患者与部分年轻亚组的内皮标志物存在差异,且老年患者接受2g氨甲环酸后血栓调节蛋白、血管紧张素2和VCAM-1显著低于安慰剂组。无任何生物标志物是28天死亡率的独立预测因子。作者认为老年患者损伤前基线内皮功能不同,氨甲环酸对老年患者内皮的作用可能更明显。

要点

  • 老年创伤患者(平均66岁)入院时血栓调节蛋白、VCAM-1和血管紧张素2中位水平显著高于年轻组(平均30岁),提示基线内皮功能不同。
  • 两组钝性创伤比例(98.1% vs 96.3%,p=0.61)、头部简明损伤定级(2.83 vs 2.93,p=0.582)和损伤严重度评分(21 vs 19,p=0.29)无显著差异。
  • 2g氨甲环酸组中,老年患者血栓调节蛋白、血管紧张素2和VCAM-1显著低于安慰剂组(p分别为0.00001、0.0032、0.0002)。
  • 2g氨甲环酸组中,老年患者 syndecan-1 水平显著高于37至54岁年轻亚组(p=0.034)。
  • 无任何内皮生物标志物是28天死亡率的独立预测因子。

适用人群与场景

  • 院前创伤性脑损伤数据库(2015-2017)中均有入院内皮生物标志物检测的创伤患者,共436例。
  • 老年组为年龄最大四分位(55-88岁,平均66岁,n=108),年轻组为其余三个四分位(15-54岁,平均30岁,n=328)。

研究设计与关键结果

  • 研究类型为回顾性二次分析,样本量436例,老年组n=108,年轻组n=328;两组钝性创伤比例98.1% vs 96.3%(p=0.61)、头部简明损伤定级均值2.83 vs 2.93(p=0.582)、损伤严重度评分均值21 vs 19(p=0.29)均无显著差异,氨甲环酸剂量无差异(p=0.571)。
  • 老年组入院时血栓调节蛋白中位693.3 vs 年轻组592.9 pg/mL(p=0.0008),VCAM-1中位70,852 vs 59,738 pg/mL(p=0.0015),血管紧张素2中位165.3 vs 134.2 pg/mL(p=0.005),老年组均较高。
  • 2g氨甲环酸组中,老年患者 syndecan-1 水平显著高于37至54岁年轻亚组(p=0.034)。
  • 2g氨甲环酸组中,老年患者血栓调节蛋白、血管紧张素2和VCAM-1显著低于安慰剂组(p=0.00001、p=0.0032、p=0.0002)。
  • 无任何生物标志物是28天死亡率的独立预测因子。

证据类型、等级与局限

  • 证据类型:回顾性二次分析;证据等级:治疗性照护管理,Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为老年患者损伤前基线内皮功能与年轻患者不同,氨甲环酸对老年创伤患者内皮的作用可能更明显。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Injured older adults account for nearly 25% of trauma admissions nationwide with increased morbidity and mortality compared with younger adults. Endothelial dysfunction has been associated with poor outcomes in trauma patients. We hypothesized that posttraumatic endothelial changes in older versus younger adult trauma patients will be different with worse outcomes in older adults.

METHODS: This is a retrospective secondary analysis of the "Tranexamic Acid (TXA) in Traumatic Brain Injury" prehospital database (2015-2017). We studied patients with admission endothelial biomarkers: intercellular adhesion molecule 1, angiotensin 1, thrombomodulin, vascular cell adhesion molecule 1 (VCAM 1), angiotensin 2, syndecan-1, and thrombospondin. We divided patients into age quartiles and compared the oldest quartile (older age [OA] group) with the three youngest quartiles (younger age [YA] group). In-hospital, discharge, and mortality outcomes were compared. Significance was set at p < 0.05.

RESULTS: A total of 436 patients were included. The mean age in OA group was 66 years (55-88 years, n = 108). The YA mean age was 30 years (15-54 years, n = 328). There was no difference between OA and YA in rates of blunt trauma (98.1% vs. 96.3%, p = 0.61), head abbreviated injury scale (mean, 2.83 vs. 2.93; p = 0.582), or Injury Severity Score (mean, 21 vs. 19; p = 0.29). Tranexamic acid dosing was not different between cohorts ( p = 0.571). Overall, the OA group had higher thrombomodulin (median, 693.3 vs. 592.9 pg/mL; p = 0.0008), VCAM 1 (median, 70,852 vs. 59,738 pg/mL; p = 0.0015), and angiotensin 2 (median, 165.3 vs. 134.2 pg/mL; p = 0.005). When comparing endothelial biomarkers of OA to each YA age quartile subsets, in the 2g TXA group OA patients had significantly higher syndecan-1 levels from a subset of YA (37 to 54-year-olds, p = 0.034). In the 2g TXA group OA patients had significantly lower plasma thrombomodulin, angiotensin 2, and VCAM 1 ( p = 0.00001, p = 0.0032, and p = 0.0002, respectively) than patients in the placebo group. None of the biomarkers were independent predictors of 28-day mortality.

CONCLUSION: Despite similar injury patterns, OA presented with higher admission endothelial plasma biomarkers. The OA patients receiving 2 g of TXA had significantly different endothelial biomarker levels versus YA group. These differences suggest that OA patients have a different baseline endothelial function prior to injury and that TXA may have a more pronounced effect on injured OA versus YA endothelium.

LEVEL OF EVIDENCE: Therapeutic Care Management; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Anand T, Mcloud S, Loss L, et al. Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial. J Trauma Acute Care Surg. 2025. PMID: 40107972. doi:10.1097/TA.0000000000004582

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。